HC Wainwright Issues Positive Forecast for Valneva Earnings

Valneva SE Sponsored ADR (NASDAQ:VALN) – Investment analysts at HC Wainwright lifted their Q3 2026 earnings estimates for shares of Valneva in a research report issued on Thursday, March 19th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($0.18) for the quarter, up from their previous forecast of ($0.19). The consensus estimate for Valneva’s current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Valneva’s FY2026 earnings at ($0.81) EPS, FY2027 earnings at $1.82 EPS, FY2028 earnings at $1.80 EPS and FY2029 earnings at $2.05 EPS.

Separately, Wall Street Zen downgraded Valneva from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Valneva has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Valneva Trading Down 1.1%

Shares of NASDAQ:VALN opened at $6.42 on Monday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.85 and a current ratio of 2.38. The stock’s 50-day moving average is $10.15 and its 200-day moving average is $9.66. The company has a market cap of $552.83 million, a P/E ratio of -4.06 and a beta of 1.80. Valneva has a 52-week low of $5.43 and a 52-week high of $12.25.

Institutional Trading of Valneva

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Frazier Life Sciences Management L.P. bought a new position in shares of Valneva during the 2nd quarter worth about $8,240,000. JPMorgan Chase & Co. bought a new stake in shares of Valneva in the third quarter valued at about $124,000. XTX Topco Ltd acquired a new stake in Valneva during the fourth quarter worth about $94,000. Marex Group plc acquired a new stake in Valneva during the second quarter worth about $64,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in Valneva during the fourth quarter valued at about $44,000. 11.39% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Valneva

Here are the key news stories impacting Valneva this week:

• Positive Sentiment: Phase‑3 data showed the Pfizer/Valneva Lyme disease vaccine demonstrated more than 70% efficacy — a clear efficacy signal that supports the product’s clinical value and underpins the companies’ plan to pursue regulatory review. Pfizer‑Valneva Lyme disease shot shows more than 70% efficacy in late‑stage trial
• Neutral Sentiment: Pfizer says it will seek regulatory approval despite the mixed readout; that keeps a potential commercial pathway open but leaves execution and regulatory hurdles unresolved. Pfizer will seek approval for its Lyme disease vaccine
• Negative Sentiment: The trial missed a pre‑specified statistical primary endpoint/margin — a key reason investors sold shares and have expressed concern about the strength of the regulatory case. WSJ: Pfizer’s Lyme vaccine shows strong efficacy but misses mark
• Negative Sentiment: Market reaction was sharp — analysts and news outlets report heavy selling and negative price action after the readout, amplifying volatility and downside pressure. VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study
• Negative Sentiment: Short interest has risen meaningfully in March (reported short interest of ~173,642 shares as of Mar 13, up ~25% vs. Feb 26) with a multi‑day days‑to‑cover ratio, which can add downward pressure if bearish bets increase. Source: short‑interest filings
• Negative Sentiment: An investor‑class action inquiry by Pomerantz LLP has been announced, which can prolong negative headlines and legal overhang for the shares. Pomerantz investigates claims on behalf of Valneva investors

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.